-
公开(公告)号:WO2010129057A3
公开(公告)日:2011-01-06
申请号:PCT/US2010001350
申请日:2010-05-07
Applicant: TETRAPHASE PHARMACEUTICALS INC , CHEN CHI-LI , CLARK ROGER B , DENG YONGHONG , HE MINSHENG , PLAMONDON LOUIS , SUN CUIXIANG , XIAO XIAO-YI
Inventor: CHEN CHI-LI , CLARK ROGER B , DENG YONGHONG , HE MINSHENG , PLAMONDON LOUIS , SUN CUIXIANG , XIAO XIAO-YI
IPC: C07C237/26 , C07C275/24 , C07C311/06 , C07C311/19 , C07D205/04 , C07D207/06 , C07D207/08 , C07D209/04 , C07D211/34 , C07D221/20 , C07D223/04 , C07D223/32 , C07D295/03
CPC classification number: C07D471/10 , C07C237/26 , C07C275/24 , C07C311/06 , C07C311/19 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/24 , C07C2602/42 , C07C2602/50 , C07C2603/46 , C07C2603/74 , C07D205/04 , C07D207/06 , C07D207/08 , C07D207/09 , C07D207/10 , C07D207/14 , C07D207/16 , C07D209/04 , C07D209/14 , C07D209/44 , C07D209/52 , C07D211/14 , C07D211/34 , C07D213/74 , C07D221/20 , C07D223/04 , C07D223/14 , C07D223/32 , C07D261/20 , C07D295/13 , C07D295/135 , C07D295/15 , C07D295/155 , C07D295/185 , C07D295/26 , C07D307/22 , C07D401/04 , C07D413/06
Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
Abstract translation: 本发明涉及由结构式(I)表示的化合物:或其药学上可接受的盐。 结构式I的变量在本文中定义。 还描述了包含结构式I的化合物及其治疗用途的药物组合物。
-
公开(公告)号:WO2010129057A2
公开(公告)日:2010-11-11
申请号:PCT/US2010/001350
申请日:2010-05-07
Applicant: TETRAPHASE PHARMACEUTICALS, INC. , CHEN, Chi-li , CLARK, Roger, B. , DENG, Yonghong , HE, Minsheng , PLAMONDON, Louis , SUN, Cuixiang , XIAO, Xiao-yi
Inventor: CHEN, Chi-li , CLARK, Roger, B. , DENG, Yonghong , HE, Minsheng , PLAMONDON, Louis , SUN, Cuixiang , XIAO, Xiao-yi
IPC: A61K31/65
CPC classification number: C07D471/10 , C07C237/26 , C07C275/24 , C07C311/06 , C07C311/19 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/24 , C07C2602/42 , C07C2602/50 , C07C2603/46 , C07C2603/74 , C07D205/04 , C07D207/06 , C07D207/08 , C07D207/09 , C07D207/10 , C07D207/14 , C07D207/16 , C07D209/04 , C07D209/14 , C07D209/44 , C07D209/52 , C07D211/14 , C07D211/34 , C07D213/74 , C07D221/20 , C07D223/04 , C07D223/14 , C07D223/32 , C07D261/20 , C07D295/13 , C07D295/135 , C07D295/15 , C07D295/155 , C07D295/185 , C07D295/26 , C07D307/22 , C07D401/04 , C07D413/06
Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
Abstract translation: 本发明涉及由结构式(I)表示的化合物或其药学上可接受的盐。 结构式I的变量在本文中定义。 还描述了包含结构式I的化合物及其治疗用途的药物组合物。
-
公开(公告)号:WO2018075767A1
公开(公告)日:2018-04-26
申请号:PCT/US2017/057385
申请日:2017-10-19
Applicant: TETRAPHASE PHARMACEUTICALS, INC. , LAFRANCE, Danny , HOGAN, Philip, C. , LIU, Yansheng , HE, Minsheng , CHEN, Chi-Li , NIU, John
Inventor: LAFRANCE, Danny , HOGAN, Philip, C. , LIU, Yansheng , HE, Minsheng , CHEN, Chi-Li , NIU, John
IPC: C07D295/15 , A61K31/65 , A61P31/00 , A61P35/00 , A61P1/00
Abstract: The invention relates to crystalline forms of the bis-HCI salt of a compound represented by Structural Formula 1, and pharmaceutical compositions comprising crystalline forms of the bis-HCL salt of a compound represented by Structural Formula 1 described herein. The crystalline forms of the bis-HCI salt of a compound of Structural Formula 1 and compositions comprising the crystalline forms of the compound of Structural Formula 1 provided herein, in particular, crystalline Form I, crystalline Form J, crystalline Form A, and crystalline Form B, or mixtures thereof, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders. Also described herein are methods for preparing the crystalline forms (e.g., Forms I, J, B and A) of the bis-HCI salt of a compound represented by Structural Formula 1.
Abstract translation: 本发明涉及由结构式1表示的化合物的双-HCl盐的结晶形式,以及包含由所述结构式1表示的化合物的双-HCL盐的结晶形式的药物组合物 于此。 结构式1的化合物的双-HCl盐的结晶形式和包含本文提供的结构式1的化合物的结晶形式的组合物,特别是结晶形式I,结晶形式J,结晶形式A和结晶形式 B或其混合物可以掺入可用于治疗各种病症的药物组合物中。 本文还描述了制备由结构式1表示的化合物的双-HCl盐的结晶形式(例如,形式I,J,B和A)的方法。 u>
-
公开(公告)号:WO2012021712A1
公开(公告)日:2012-02-16
申请号:PCT/US2011/047428
申请日:2011-08-11
Applicant: TETRAPHASE PHARMACEUTICALS, INC. , CHEN, Chi-Li , CLARK, Roger, B. , DENG, Yonghong , PLAMONDON, Louis , SUN, Cuixiang , XIAO, Xiao-Yi
Inventor: CHEN, Chi-Li , CLARK, Roger, B. , DENG, Yonghong , PLAMONDON, Louis , SUN, Cuixiang , XIAO, Xiao-Yi
IPC: A61K31/535 , C07D413/00 , C07D487/00 , C07D207/00 , A01N43/46 , A61K31/40
CPC classification number: A01N43/90 , A01N43/36 , A01N43/40 , A01N43/60 , A01N43/80 , A01N43/84 , C07D205/04 , C07D207/09 , C07D207/12 , C07D207/20 , C07D209/52 , C07D211/26 , C07D211/38 , C07D213/73 , C07D223/04 , C07D231/12 , C07D233/64 , C07D241/04 , C07D261/20 , C07D265/30 , C07D413/04 , C07D471/08
Abstract: The present invention is directed to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.
Abstract translation: 本发明涉及由结构式(I)表示的化合物或其药学上可接受的盐。 结构式(I)的变量在本文中定义。 还描述了包含结构式(I)的化合物及其治疗用途的药物组合物。
-
公开(公告)号:WO2010129057A8
公开(公告)日:2011-02-24
申请号:PCT/US2010001350
申请日:2010-05-07
Applicant: TETRAPHASE PHARMACEUTICALS INC , CHEN CHI-LI , CLARK ROGER B , DENG YONGHONG , HE MINSHENG , PLAMONDON LOUIS , SUN CUIXIANG , XIAO XIAO-YI
Inventor: CHEN CHI-LI , CLARK ROGER B , DENG YONGHONG , HE MINSHENG , PLAMONDON LOUIS , SUN CUIXIANG , XIAO XIAO-YI
IPC: C07C237/26 , C07C275/24 , C07C311/06 , C07C311/19 , C07D205/04 , C07D207/06 , C07D207/08 , C07D209/04 , C07D211/34 , C07D221/20 , C07D223/04 , C07D223/32 , C07D295/03
CPC classification number: C07D471/10 , C07C237/26 , C07C275/24 , C07C311/06 , C07C311/19 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/24 , C07C2602/42 , C07C2602/50 , C07C2603/46 , C07C2603/74 , C07D205/04 , C07D207/06 , C07D207/08 , C07D207/09 , C07D207/10 , C07D207/14 , C07D207/16 , C07D209/04 , C07D209/14 , C07D209/44 , C07D209/52 , C07D211/14 , C07D211/34 , C07D213/74 , C07D221/20 , C07D223/04 , C07D223/14 , C07D223/32 , C07D261/20 , C07D295/13 , C07D295/135 , C07D295/15 , C07D295/155 , C07D295/185 , C07D295/26 , C07D307/22 , C07D401/04 , C07D413/06
Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
Abstract translation: 本发明涉及由结构式(I)表示的化合物或其药学上可接受的盐。 结构式I的变量在本文中定义。 还描述了包含结构式I的化合物及其治疗用途的药物组合物。
-
-
-
-